Section 1Global Biologic Market and Market Access
Lecture 1Introduction to Biopharmaceuticals and Biopharmaceutical Market
Lecture 2Classification of Biopharmaceutical
Lecture 3Chemical Drugs Vs. Biologic Drugs
Lecture 4Principle of Naming of Biologics
Lecture 5Global Biopharma Market Overview – Product, Application & Regional Dynamics
Lecture 6Classes of Biologics – Comprehensive Classification & Subclasses
Lecture 7Global Biopharmaceutical Market | Market Size | Growth | Regional Shares| Top Therapy Areas | Innovation Pipeline
Lecture 8Global Biologic Market Trends
Lecture 9Introduction to Market Access | Objectives | Various Key Terminologies | Steps of Market Access | Understanding on Pricing and Reimbursement
Lecture 10Market Access Strategic Planning : Steps and Logical Sequencing for Market Access Strategy Development
Lecture 11Indication Sequencing | Indication Prioritization | Development of Indication Timeline | Indication Matrix | Value Based Indication Prioritization
Lecture 12Indication Prioritization Case Study
Lecture 13Market Access Value Dossier : What it is | Significance | Components | What to include
Lecture 14AMCP Market Access Dossier Preparation
Lecture 15Target product profile (TPP) | Quality Target product profile (QTPP) | Critical Quality Attributes (CQAs) | Quality By Design (QbD)
Lecture 16Practical Training on Value Dossier Preparation | Sample Value Dossier with each section with data | Key points to consider while preparing value dossier
Lecture 17Clinical Data in Value Dossier | Understanding in different types of clinical study with rationale | Case based example on clinical study section writing
Lecture 18Pipeline in a molecule | Case Study
Lecture 19Global Regulatory Agencies & Framework for Biologics (ICH + Regional Integration)
Lecture 20ICH Q5 Series & Q6B – Deep Dive into Biologic-Specific Guidelines
Lecture 21Biologic CMC Deep Dive – Cell Line, Upstream & Downstream Processing
Section 2Biopharmaceutical Classification and study on each class
Lecture 22Advanced Understanding on Structure of Monoclonal Antibody (MAB)
Lecture 23Monoclonal Antibodies Vs. Polyclonal Antibodies
Lecture 24Monoclonal Antibodies : Detailed Understanding
Lecture 25Simulation on MAB Structural Interpretation
Lecture 26Production of Monoclonal Antibodies
Lecture 27Structural Comparison of Adalimumab and Trastuzumab | Structural Influence on Therapeutic Targeting | Structural Engineering Example
Lecture 28Structural Comparison of Adalimumab and Trastuzumab | Structural Influence on Therapeutic Targeting | Structural Engineering Example
Lecture 29Trastuzumab – Structural Design and Therapeutic Outcome
Lecture 30Bevacizumab – Structural Design and Therapeutic Outcome
Lecture 31mAB - At a glance
Lecture 32Cytokine Know How - Explainer
Lecture 33Cytokines - Product Class Orientation
Lecture 34Vaccine Advanced Tech - Fundamental Understanding | Class Explainer
Lecture 35Recombinant protein
Lecture 36Synthetic Immunomodulators
Lecture 37Interferon
Lecture 38Erythropoiesis-stimulating agent
Lecture 39Blood Biologics Technology Understanding
Lecture 40ATMPs - at a glance
Lecture 41CAR-T Therapy | Different Types of CAR-T Therapy | Mechanism of action | Challenges | Brainstorming on Concept of Personalized Medicine | Understanding on marketed formulation
Lecture 42Live Biotherapeutic Products | LBPs | Class | Mechanism | Indication Positioning | Regulatory Requirements for LBPs
Lecture 43ATMPs | Types and Classification | Regulatory Mechanism
Lecture 44ATMPs - at a glance
Lecture 45ATMPs Deep Drive | ATMP Classification Framework | Manufacturing | CRISPR Gene Editing | Regulatory Requirements
Lecture 46LBP Strategy and RA Development | Manufacturing Process | CMC Requirements
Lecture 47Decoding Biologic Complexity
Lecture 48Biologic Class Documentation Guide | Modality Specific Checklists
Section 3Biopharmaceutical Regulatory Pathways | US Regulation
Lecture 49R&D Process & Introduction to discovery, development to commercialization process
Lecture 50Investigational New Drug Application (INDA)
Lecture 51New Drug Application (NDA)
Lecture 52 Biological Licensing Application (BLA)
Lecture 53Basic concept and understanding of the Generic Drug
Lecture 54Abbreviated New Drug Application (ANDA)
Lecture 55Abbreviated Biosimilar Application - 351(k): Advance Strategic Planning Process : Originator Vs. Biosimilar Development and Regulatory Approval Process | Reference Biologic | Purple Book | Data Requirements
Lecture 56505(j) ANDA, 505(b)(2) NDA, 505(b)(1) NDA
Lecture 57Purple Book: Significance | Searching | Assignments
Lecture 58Nomenclature of Biosimilars - How biosimilar names are built, why they matter, and what regulators expect
Lecture 59Biosimilar Naming – Examples & Principles
Lecture 60Vaccine development and approval Process
Lecture 61Clinical Trials Terminologies
Lecture 62Advance Learning on 505B2 Pathway
Lecture 63FDA Forms and How to fill the resources
Lecture 64Chemistry, Manufacturing & Controls
Lecture 65Strategic Discussion: PreIND, EOP1, EOP2 - What to expect !
Lecture 66Patent & Exclusivity - Strategic Understanding | Patent Restoration| Orphan Drug Exclusivity (ODE)
Lecture 67USFDA expedited programs for Pharmaceuticals and Biopharmaceuticals
Lecture 68Practical Queries on different USFDA application and Filing
Lecture 69REMS Strategic Planning
Lecture 70U.S. Biologic Regulatory Pathways and Market Access - Innovator Biologics + Biosimilars + Commercial Access Execution
Lecture 71Biologic CMC Review | Review Expectations
Section 4EU Regulation - Discovery Development to Commercialization
Lecture 72EU Regulatory System Fundamentals
Lecture 73Introduction to EU Regulation
Lecture 74Orientation to European Countries and National Regulatory Bodies
Lecture 75EMA and EMA Authorisation Process
Lecture 76EMA and EMA Authorisation Process
Lecture 77Centralised vs DCP vs MRP vs National Procedure - Detailed Strategic Insight
Lecture 78EU MA Application Types and Strategic Planning
Lecture 79EU MA Procedure - Centralised, Decentralised, Mutual Recognition, National Procedure
Lecture 80EU MA Strategic Planning: Full, Full-mixed, hybrid applications. Generic, Similar biologic application pathway, Well-established use application, Fixed combination application, Informed consent application
Lecture 81Validity of the EU MA - Renewal steps, Cessation of the marketing authorisation, Significance of "Placed in Union Market", Suspension or withdrawal & EU MA for licensed products
Lecture 82Structured Practical understanding of EU legal bases | Understanding Data Requirements
Lecture 83Practical understanding of EU legal bases for Marketing Authorisation Applications (MAA) | Decision Tree
Lecture 84Centralised Procedure Timetable and Review Logic
Lecture 85DCP / MRP / National Procedure – Practical Workflow Module
Lecture 86EU Procedures Critical Operational Steps - Validation • Clock-Stop • List of Questions • Approval • National Phase
Lecture 87DCP vs MRP Timeline
Lecture 88EU Adaptive Pathway
Lecture 89European public assessment report (EPAR) - Importance, Component, Management, Updation
Lecture 90SPOR - Concept of Master Data Management
Lecture 91The 'sunset clause' for marketing authorisation of pharmaceuticals
Lecture 92LoQ Response Strategy - EU Regulatory Procedures (CP / DCP / MRP) – Winning the Day 120 / Mid-Cycle Response
Lecture 93Response to list of Questions (LoQ)
Lecture 94Response to list of outstanding issues (LoOI) - Day 180 / Final Assessment Phase Response
Lecture 95Oral Explanation Training Module - CHMP / CMDh Oral Defence Strategy – From Data to Approval
Lecture 96CHMP - Question Bank Real-Life Regulatory Questions + Model Answers (CP / DCP / MRP)
Lecture 97Conditional marketing authorisation | Marketing authorisation under exceptional circumstances
Lecture 98Compassionate Use
Lecture 99EU Prime Designation
Lecture 100MHRA - UK Regulation
Lecture 101Summary of Product Characteristics
Lecture 102Drug Registration and Submission Strategic Planning for Russia and EAEU region
Lecture 103Accelerated assessment by EMEA
Lecture 104Certificate of Suitability (CEP) | Significance | Importance | Understanding Regulatory Compliance and Submission Process | Walkthrough
Lecture 105CEP Dossier DMF - Differences
Lecture 106Policy 0070 | RPDP Submission and Management timeline | Anonymisation Report (AnR) - Significance | AnR in FRDP
Lecture 107Comprehensive EU Clinical Trial Regulatory Affairs – CTA, CTIS, Strategy & Execution
Lecture 108CTIS Operating Model – Advanced EUClinical Trial Execution Module
Lecture 109CTA Structure: Part I / Part II (EU Clinical Trials Regulation)
Lecture 110Country-wise Part II Requirement Master
Lecture 111CTIS Hands-on Simulation Module Step-by-Step Clinical Trial Submission Exercise (CTR Execution Training)
Lecture 112EU CTR Advanced Module - Substantial Modifications, Safety Reporting, Transition Lessons & End-of-Trial Obligation
Lecture 113IMPD | Significance | Format of IMPD | Differences with CTA, IB, IND
Lecture 114Investigator’s Brochure | Significance | Format of IB | Preparing different sections of IB
Lecture 115Patent Landscape & Freedom to Operate (FTO) – EU Perspective - Strategic Regulatory + IP Integration Module (Drugs & Biologics)
Lecture 116EU Data Exclusivity, Market Protection & Orphan Exclusivity
Lecture 117Data Exclusivity and Market Protection - Supplementary Patent Protection, Exclusivity, 6/10 Rule, 8+2+1 Formulae
Lecture 118EU Orphan Medicinal Products Regulation
Lecture 119Paediatric use marketing authorisation (PUMA) & Paediatric Investigation Plan (PIP)
Lecture 120EU Supplementary Protection Certificates (SPC) & Paediatric Rewards
Lecture 121Patent vs Regulatory Exclusivity vs Trademark vs Launch Sequencing (EU Perspective)
Lecture 122“No EU-Style Patent Linkage” – What It Really Means (EU vs US)
Lecture 123EU vs US Regulatory–IP Framework
Lecture 124Global Patent + Exclusivity Timeline Dashboard - Executive-Level Strategic Tool (EU + US + Global Integration)
Lecture 125Full EU Submission Strategy Planner
Lecture 126CHMP Question Bank - Regulatory Questions (CP / DCP / MRP – EU Focus)
Lecture 127Biologics-Specific Question Bank - CHMP / CAT / PRAC-Style Questions
Lecture 128Biosimilar Road Map
Lecture 129ATMP Strategic Submission Pathways – EU vs US
Lecture 130Regulatory Submission Pathways – BLA, MAA & Global Filing Strategy
Section 5Innovation Management and Strategic Pathway for Biologic and Biosimilar
Lecture 131Introduction to Intellectual Property in Life Sciences | Types of IP | Introduction to Patent Portfolio Strategy
Lecture 132Global Pharmaceutical Patent Landscape | Strategic Overview of Global Patent Filing and Protection
Lecture 133Understanding on Patent System
Lecture 134Global Pharmaceutical Patent Filing Strategy
Lecture 135PCT Patent Filing Flow
Lecture 136Patentability Criteria in Pharmaceuticals | Practical Case Study
Lecture 137Patent Law Framework for Pharmaceuticals
Lecture 138Understanding and Decoding Section 3(d) of the Indian Patent Act | Case Based Analysis
Lecture 139Evergreening vs Genuine Innovation in Pharmaceutical Patents | Evergreening and Genuine Innovation Evaluation
Lecture 140Pharmaceutical Patent Lifecycle - Integrated Layer Strategy
Lecture 141Blockbuster Drug Patent Thicket Strategy
Lecture 142New Indication Approval Process and Promotion
Lecture 143Biosimilar Approval and Patent Management | Strategic Pathway of Patent Negotiation and Litigation in Biosimilar Approval | Patent Dance | FAQs on Biologic Patent Management
Lecture 144Biosimilar launch case study | Patent Dance Framework
Lecture 145Biosimilar Launch Framework
Lecture 146Biosimilar 180 Day Notice
Lecture 1473(A) List | Significance | Importance | How to interpret
Lecture 148Steps to win over innovator patents | Step wise planning
Lecture 149Biosimilar Launch Project Roadmap with defined stages of project
Lecture 150Timing of Biosimilar Submission and Approvals | Two Scenario based timeline assessments
Lecture 151Hands on Training on Reference Biologic Patent | Classify RPS Biologic Patents | Case Simulation
Lecture 152How to work on RPS’s Patent | Walkthrough | Case Study
Lecture 153Biosimilar Launch Project With Milestones
Lecture 154Analysis of Biologic Patents | Work Assignments
Lecture 155Biologic Patent Insight Worksheet
Lecture 156Patent Thickets | Concept | Implication | Case Based Learning
Lecture 157Understanding Patent Searching Process
Lecture 158IPC and CPC - Importance and Significance in Patent Search
Lecture 159IPC Structures for Pharmaceutical Patents
Lecture 160Freedom-to-Operate (FTO) | FTO Risk Assessment | Strategic Management
Lecture 161FTO Decision Tree – Generic Drug Launch Strategy
Lecture 162Fundamental of Pharmaceutical Patent Drafting | Structure | Component | Claim Anatomy | Effective Claim Writing
Lecture 163Pharmaceutical Patent Risk Management Framework
Lecture 164Patent Claim Coverage - Practical Example
Lecture 165Pharmaceutical Patent Filing Procedure and Global Filing Strategy | PCT Filing | Timeline
Lecture 166Advanced Understanding on Patent Opposition and Patent Litigation in Pharmaceutical Domain
Lecture 167Patent Prosecution and Handling Examiner Objections
Lecture 168Pharmaceutical Patent Portfolio Management | How to build and manage pharma patent portfolio
Lecture 169Pharmaceutical Patent Valuation and Licensing
Section 6Bio-manufacturing | Biosimilar Development | CMC requirements
Lecture 170Biologic Lifecycle and CMC Submission Core Philosophy
Lecture 171Biologic Manufacturing Overview from CMC Writing Point of View
Lecture 172Bio-Manufacturing Process Information
Lecture 173Fundamental Understanding on Biologic Manufacturing Upstream Process
Lecture 174Fundamental Understanding on Immunogenicity In Biologics
Lecture 175Comparability of Biologics | Different Categories of Comparability | General Principles
Lecture 176Immunogenicity Assessment & Risk Management in Biologics
Lecture 177Immunogenicity In Biologics - Regulatory Strategy, Risk Assessment & CMC Writing Integration
Lecture 178Immunogenicity Case Studies
Lecture 179Immunogenicity Capstone Simulation - CMC immunogenicity justification | Control strategy update | QOS summary
Lecture 180Immunogenicity Advanced Case Writing
Lecture 181Download End-To-End Immunogenicity Case Simulation Workbook
Lecture 182Immunogenicity + ADA assay + Risk matrix
Lecture 183Master Module: Biologic Comparability - Process Changes, Biosimilarity & Regulatory Justification Framework
Lecture 184Biologic Comparability Protocol Template - Process Change / Post-Approval Change / Scale-Up / Site Transfer
Lecture 185Critical Quality Attributes (CQAs) & Critical Process Parameters (CPPs)
Lecture 186Analytical Characterization of Biologics (Structure, Purity, Potency)
Lecture 187Non-Clinical Development of Biologics: ICH S6 Requirements, Study Design & Regulatory Strategy
Lecture 188Clinical Development Strategy for Biologics: Phase I–III Design, Adaptive Trials & Regulatory Alignment
Lecture 189CQAs & CPPs in Biologics – Practical Case-Based Workbook
Lecture 190Stability Studies for Biologics (ICH Q5C + Real-Time Strategy)
Lecture 191ICH Q5C Guideline
Lecture 192Biologic Dossier Evaluation Explainer
Lecture 193Mastering Fermentation and Bioreactors Process Documentations
Lecture 194Justifying Fermentation Variances
Lecture 195Mastering The Scientific Architecture of Biologic Documentation
Lecture 196Guide to Biologic Regulatory Writing | Process Defines The Product | Detailed Step By Step Understanding
Lecture 197The Process is the Product | Why Biologic Data Fails without a Narrative
Lecture 198Biologic CMC Mastery | Translating Process Science Into Regulatory Confidence | Biologic Manufacturing for CMC Writer
Lecture 199CMC Immunogenicity Control Strategy Capstone
Lecture 200CMC Immunogenicity Case Briefing on Batch Variation Observed
Lecture 201Navigating Biologic Common Technical Document | A Strategic Case Study
Lecture 202Biosimilar Development Process
Lecture 203Strategic Consideration for Biosimilar Development
Lecture 204Regulatory Requirements for Biosimilar | Stepwise evidence based development | Analytical Similarity | Clinical Study | PKPD study requirements | CMC expectation of Biosimilar
Lecture 205Studies required for approval of biosimilar
Lecture 206Mapping Upstream Bioprocessing for effective CMC Documentation
Lecture 207Downstream Purification Narrative Writing in Biologic CMC Documentation
Lecture 208Upstream Process Review | Shaping Biologic Quality and Regulatory Process
Lecture 209Upstream Processing Documentation | Process-Product Linkage | Metabolic Control | Regulatory Storytelling for CMC
Lecture 210Blueprint of Purity | Understanding Complex Downstream Processing
Lecture 211Writing Downstream Narratives : Translating Purification Science into Reviewer-oriented CMC Documentation
Section 7 Submission Dossier | Publishing | Biologic CMC Review
Lecture 212Introduction to Common Technical Document (CTD)
Lecture 213CMC Dossier & Compliance Management
Lecture 214Fundamental of CMC | Detailed understanding of CMC section writing | Important Points regarding CMC | Drug Product and Drug Substance | Excipient, FP, Analysis and Stability Study Requirements
Lecture 215CMC Dossier & Compliance Management
Lecture 216Introduction to Electronic Common Technical Document (ECTD)
Lecture 217Advance Practical Training on Dossier Preparation focusing on drug registration in export countries
Lecture 218Importance of effective dossier management
Lecture 219Discussion on 85 common deficiencies in CTD submission dossier
Lecture 220Certificate of Analysis
Lecture 221Detailed Understanding on ANDA Submission Dossier
Lecture 222Prior Approval Submission
Lecture 223Regulatory Requirements for Biosimilar | Stepwise evidence based development | Analytical Similarity | Clinical Study | PKPD study requirements | CMC expectation of Biosimilar
Lecture 224CMC Writing Case Study | Successful Documentation
Lecture 225Structure for CMC Writing | Understanding 3.2.S and 3.2.P section | Documents requirements | Case Study
Lecture 226Well written Vs. Poorly Written CMC Section | Practical Example
Lecture 227Drug Substance Section in CMC | Documentations | Practical Examples | Do’s and Don’ts
Lecture 228Example of Well-Written Drug Substance Characterization | Impurities and Degradation Products | Well-Written Impurities and Degradation Products | Synthesis and Manufacturing Processes | Control of Drug Substance (Specifications, Testing, and Acceptance Criteria)
Lecture 229Stability Studies and Data Presentation in CMC Writing | Case Based Analysis of Stability Study Data Presentation | Interpretation of stability data
Lecture 230Developing Specifications for a New API
Lecture 231Example of Manufacturing Process and Controls
Lecture 232Interpretation of Stability Table
Lecture 233Critical Stability Scenarios | 8 Different Case Studies | Stability Study - Outcome based action plan creation
Lecture 234Common Pitfalls in CMC Writing and How to Avoid Them | Case Study
Lecture 235Grouped Submission | Significance | Importance in Market Access and Regulatory point of view | Case Study
Lecture 236Process Validation Report (PVR) | Sample Process Validation Report Analysis | CPPs and CQAs identification
Lecture 237Case Study - Omissions of CPPs in PVR | Case insight, explanation, action plan | Correlations - CPPs - CQAs - IPCs
Lecture 238Biologic Lifecycle and CMC Submission Core Philosophy
Section 8Stability Study
Lecture 239Modules on Stability Study : Stability Study - Fundamental Understanding | Interchangebility | Reports | API & FPP Stability Study
Lecture 240Climatic Zone and Stability Study Conditions as per ICH Guidelines
Lecture 241Stability Zone Finder
Lecture 242Stability Studies Case Discussions
Lecture 243Case Study: Managing Stability Study for Zone IV countries
Lecture 244Accelerated and intermediate testing conditions
Lecture 245Long Term Stability Testing Requirements
Lecture 246Testing Frequency
Lecture 247Bracketing
Lecture 248Matrixing
Lecture 249Critical Stability Issues - Database | Implication | Action Plan
Lecture 250Stability Study Requirements for Biologics - Regulatory, Registration, Lifecycle & Control Strategy Module
Lecture 251Advanced Case Study - Stability Requirements - EU, U.S., and Other Regions – Detailed Regulatory Planning
Lecture 252Biologic Stability Requirement Study Decision-Making Pathways - Step-by-Step Regulatory Planning Framework
Lecture 253Stability Studies Case Discussions
Section 9Bioequivalence Study
Lecture 254PKPD in Drug Discovery | PK-PD trial | Understanding PKPD from regulatory perspective in drug approval process
Lecture 255Bioequivalence Study | Study design | Different types of BE Studies
Lecture 256Bioequivalence Study | Study design | Parallel Study | Crossover study design | Other alternative study designs | Blood Sampling Planning | Analyte | Bioanalytical Methods Validation | Statistical Model | Ln Transformation | Dose normalisation | Confidence interval acceptance criteria
Lecture 257Biopharmaceutical Classification System (BCS) | Types | Biowaivers | BCS tool for drug development and regulatory submission
Lecture 258Bioequivalence Study - Discussion - Timeline of stability study and bioequivalence study
Lecture 259Bioequivalence Study - Discussion - Dissolution Testing
Lecture 260Bioequivalence Study - Generic Approval and Additives Labeling Requirements
Lecture 261BA BE Study Design | Comparing different types of the study design
Lecture 2622wco Study Design | Design Table | Importance
Lecture 2633wco Study Design | Design Table | Importance
Lecture 264FRCO Study Design | Design Table | Importance
Lecture 265Parallel Vs. Crossover Study Design
Section 10Variation Management
Lecture 266Introduction to Variation Management | Reasons for Variation | Working in Variation Department
Lecture 267Variation Classification | Basis of Classification | US and EU Variation Classification | Other region variation guideline.
Section 11Quality issues, Warning Letter, CAPA and Data Integrity
Lecture 268Data Integrity
Lecture 269Establishment Inspection Report | 483 Observations | USFDA Warning Letter | Handling of FDA inspection | Closing of Warning Letter
Lecture 270Electronic Batch Record for effective compliance management | Key Understanding | Functionalities | Importance in managing data integrity
Lecture 271RTQs | Response to Queries | How to handle Regulatory Queries
Section 12Drug Master File and Site Master File
Lecture 272Key Consideration for Drug Master File Preparation and Submission
Lecture 273Practical Understanding on Drug Master File Preparation and Submission
Lecture 274Associated Learning: Site Master File - Detailed Understanding
Lecture 275DMF Completeness Assessment
Lecture 276Drug Master File - Fees
Lecture 277Drug Master File - Global Perspective [Across Different Regions]
Lecture 278Drug Master File (DMF) Strategy & Regulatory Requirements for Biologics (CMC Focus)
Section 13ASEAN Region - Biologic Regulation, Registration and Strategic Planning
Lecture 279ASEAN Drug Regulations : Comparison Study | Guidelines | Pharmaceutical products Regulatory Submissions | Pharmacopoeia Requirements | stability requirements | Pharmacovigilance | Product labeling | Drug variation information (Prime Session)
Lecture 280Drug Registration and Regulation Singapore | Strategic Pathways for Marketing Authorization | Screening, Evaluation of MA applications | Variations Classifications and Management
Lecture 281Registration and Regulation in Brunei
Lecture 282Registration and Regulation in Cambodia
Section 14African Region - Biologic Regulation, Registration and Strategic Planning
Lecture 283African Continent Overview - Brief introduction to course
Lecture 284African Pharma Market
Lecture 285Drug Registration - African medicines regulatory agencies
Lecture 286Basic Export Requirement for African Countries
Lecture 287Export Documentations & Important Concepts
Lecture 288Nigeria - Drug Registration
Lecture 289Drug Registration in Algeria
Lecture 290Drug Registration in Ethiopia
Lecture 291Drug Registration in Kenya
Lecture 292Drug Registration in Egypt
Lecture 293Drug Registration in Ghana
Lecture 294Drug Registration in Botswana
Lecture 295Drug Registration and Regulation in Uganda
Lecture 296Drug Registration in Zambia
Section 15LATAM Region - Biologic Regulation, Registration and Strategic Planning
Lecture 297Introduction to Latam
Lecture 298Drug Registration and Regulation in Argentina
Lecture 299Drug Registration and Regulation in Bolivia
Lecture 300Drug Registration and Regulation in Brazil
Lecture 301Drug Registration and Regulation in CHILE
Lecture 302Drug Registration and Regulation in Colombia
Lecture 303Drug Registration and Regulation in Mexico
Lecture 304Drug regulation and registration in El Salvador
Lecture 305Central America Drug Regulatory Affairs | Panama, Costa Rica, Guatemala, El Salvador, Honduras, Dominican Republic | RTCA guideline [2022]
Lecture 306Drug regulation and registration in Peru
Lecture 307Drug regulation and registration in Honduras
Lecture 308LATAM Country Clusters & Comparative Regulatory Logic | Wave Filing Strategy
Lecture 309Strategic Understanding on Delta Documentation
Lecture 310Marketing Authorization Framework Across LATAM
Lecture 311LATAM Dossier Structure Differences Matrix
Lecture 312Language Requirements for Latam Filing
Lecture 313ANVISA Regulatory Submission | Delta Packages | CMC | Stability Decision Tree | Case Study
Lecture 314Case Study - ANVISA Submission for generic pharmaceutical | Critical Steps | Pathways | Risk Analysis and Mitigation Strategy
Lecture 315COFEPRIS (Mexico) Regulatory Submission | NCE Pathways | NOM-177 Requirements
Lecture 316Stability Requirements for Pharmaceutical Products in Mexico (COFEPRIS)
Lecture 317LATAM Stability Requirement Comparison (Brazil vs Mexico vs Argentina vs Chile)
Lecture 318Global Stability Program Supporting LATAM Registrations
Lecture 319LATAM Review Test | Check your competency
Lecture 320LATAM Marketing Authorization Simulation
Section 16GCC / Middle East Region - Biologic Regulation, Registration and Strategic Planning
Lecture 321Middle East / MENA / GCC Countries Geographical Orientation
Lecture 322Middle East / MENA / GCC Countries National Regulatory Agencies
Lecture 323GCC Registration Procedure - Centralized and Decentralized Procedure | Detailed understanding on Centralized Registration Process
Lecture 324Drug Registration in Saudi Arabia
Lecture 325Drug Registration in UAE
Lecture 326Drug Registration and Regulatory Strategic Planning for Iran
Lecture 327Drug Registration and Regulatory Strategic Planning for Israel
Lecture 328Drug Registration and Regulatory Strategic Planning for Jordan
Lecture 329Drug Registration and Regulatory Strategic Planning for Iraq
Section 17China - Biologic Regulation, Registration and Strategic Planning
Lecture 330Registration and Regulation in China
Lecture 331New Update: NMPA's the Drug Registration Regulation (DRR) and the Drug Manufacturing Regulation (DMR)
Section 18Russia / EAEU Region - Biologic Regulation, Registration and Strategic Planning
Lecture 332Registration and Submission Strategic Planning for Russia and EAEU region
Lecture 333GMP requirements in Russia
Section 19Japan - Biologic Regulation, Registration and Strategic Planning
Lecture 334Introduction to Japan Drug Regulatory Affairs
Lecture 335Drug Discovery Development to commercialization | PMDA functions | Consultation | Premarket to post market approval
Lecture 336Drug Approval System | GCP | PMDA requirements
Lecture 337New Drug Application | Requirements | Review Process
Lecture 338Generic Drug Application Review and Approval
Lecture 339Marketing Authorization Process for registration of pharmaceutical in Japan
Lecture 340API Registration in Japan | Step By Step Process
Lecture 341Generic Registration | Patent - Patent Term Extension | Exclusivity | Re-examination System | Pediatric Designation | Patent Term Extension Case Studies
Lecture 342Priority Review Application | Criteria | Review Process | Timeline
Lecture 343Orphan Drug Designation in Japan
Lecture 344Japan DMF System | MF filing Process | Key points
Lecture 345Strategic Approval Pathway - Formulation Approval Quoting MF
Lecture 346SAKIGAKE designation
Section 20Introduction to AI in Regulatory Affairs
Lecture 347Introduction to AI
Lecture 348Basics of AI ML DL | Key Differences | Application in industry
Lecture 349Types of AI
Lecture 350AI Project | Overview
Lecture 351Comprehensive Training on AI Project | Managing Stages | AI Iteration
Lecture 352How machine learning
Lecture 353Understanding Regulatory Affairs – Traditional vs. Digital | 2 Case Study
Lecture 354Basics of AI for Regulatory Professionals | Understanding different models used in RA | Case Study | Simulation
Lecture 355AI Terms with Regulatory Significance | Regulatory Applications
Lecture 356NLP in Regulatory Affairs | Conceptual understanding | Usage | NLP in Labeling
Lecture 357Data Grouping with Unsupervised Learning | Case Simulation | Hands on Exercise
Lecture 358Quality Data and Bias | Bias in datasets | Different Types of Bias in Pharma Datasets
Lecture 359AI Data Quality Standard | Checklist
Lecture 360Download AI Data Quality Checklist
Lecture 361Case Study: Accelerated Approval Using Real-World Evidence AI
Lecture 362AI Model for Dossier Submission and Filing - Model Selection | Simulation
Lecture 363AI Technologies in RA
Lecture 364Structured Vs. Unstructured Data | Practical Understanding | Explore Patient Datasets
Lecture 365Sample Data Exercise | Data error | Data Refinement and Cleaning of the data
Section 21AI in Regulatory Authoring and CMC Writing
Lecture 366AI-Powered Regulatory Document Authoring and CMC Writing
Lecture 367AI Tools Comparison - Authoring and CMC Writing (Module 2 & 3)
Lecture 368Tips for Selecting AI Tools (CMC Authoring)
Lecture 369CMC - AI Workflow Checklist | Simulation Based Cases
Lecture 370HITL Regulatory Document Authoring
Lecture 371Confidence Score in Regulatory Authoring | Case Simulation in CMC Authoring
Lecture 372Confidence Scores in Data Extract in Regulatory Writing [Case Simulation]
Section 22eCTD v4.0 Training
Lecture 373eCTDV4.0 Fundamental Understanding | Structures | Key Features
Lecture 374eCTDV4.0 Structure | Lifecycle Management
Lecture 375eCTD Validation | Managing Validation | Tool Types | Types of Error | Validation Error Management
Lecture 376eCTD Validation Tools
Lecture 377eCTD Publishing Cycle
Lecture 378HL7 - Structure and Understanding in the context of eCTD V4.0
Lecture 379Tips and Submission Readiness Checklist
Lecture 380eCTD Submission Checklist Format
Lecture 381Regulatory Publishing Document Control Challenges
Lecture 382Document Control Checklist
Lecture 383Leaf Structure Analysis | Common Error in Leaf Structuring
Lecture 384Formatting Rules Templated and Agency Specification
Lecture 385Versioning for Regulatory Publishing
Lecture 386File Naming Standard
Lecture 387Text Recognition and Optical Character Recognition (OCR)
Lecture 388Versioning File Naming OCR - How they work together
Lecture 389Final Document Assembly
Lecture 390Visual Diagram : eCTD Structure and XML Hierarchy
Lecture 391TOC and CI Management
Lecture 392Initial Submission & Maintenance Submission
Lecture 393Managing Lifecycle Operators - NEW REPLACE DELETE APPEND
Lecture 394eCTD Dossier Lifecycle - Multi Sequence View
Lecture 39510 Year eCTD Lifecycle : Sequence Evolution Diagram
Lecture 396Global Decision Tree - Classifying Post Approval Changes
Lecture 397eCTD Technical Validation | Typical issues | Resolutions
Lecture 398eCTD Validation Readiness Checklist
Lecture 399QC Checklist Design and Pre Submission Review
Lecture 400Submission Gateway | FDA ESG • EMA CESP • Health Canada Portal • PMDA Gateway
Lecture 401Regulatory Publishing Simulation
Lecture 402Pre-Gateway Submission Review Checklist | Post Submission Confirmation
Section 23Risk and Compliance Management
Lecture 403AI and Data Integrity | Regulatory Documentation | Case Based Learning | Understanding Data Integrity Principles | Application and Use Cases
Lecture 404Cases of data breaches with explanation
Lecture 405Case Based Discussion : Data Breach in AI-Assisted CMC Drafting
Section 24Labelling and CCDS Management
Lecture 406CCDS Management
Lecture 407CCDS Management Tools - Native, AI Plus | Key Functionalities
Lecture 408AI Augmented Labelling Compliance System
Lecture 409Label Drift in CCDS Management | Simulation Case Study | AI Based Workflow in Label Drift detection and management
Lecture 410AI Review of Labels, PI and SMPC with help of the Case Based Simulation | 4 Case Simulations
Lecture 411CCDS Management Case Study | Pregnancy Warning Upgrade Case Study
Lecture 412CCDS Management Case Study | Dosage Section Conflict | Case Based Analysis
Lecture 413Centralized Artwork Operation | Mechanism | Operation Step Planning
Lecture 414Case Study on Centralized Artwork Operation [Recall Management]
Lecture 415Artwork Management Terms | Key Understanding on Terminologies | Usage in Artwork Cases
Lecture 416Introduction to Labelling | Regulatory vs Commercial Perspective of Labelling | Labelling Compliance Function
Lecture 417Artwork & Packaging Lifecycle | Artwork Management Lifecycle Workflow
Lecture 418Global Artwork Labelling Framework | 5 Case Simulation
Lecture 419Country-Specific Labelling Requirements
Lecture 420Summary of Product Characteristics (SmPC)
Lecture 421Patient Information Leaflet (PIL)
Lecture 422Summary of Product Characteristics (SmPC) – Review Checklist
Lecture 423Patient Information Leaflet (PIL) – Review Checklist
Lecture 424US Prescribing Information (PI) | Differences with EU SmPC
Lecture 425US Prescribing Information (PI) - Review Checklist
Lecture 426Fundamental Understanding on Medication Guide
Lecture 427Regulatory Decision Flow: When Is a Medication Guide Required? - Step Based Decision Making
Lecture 428Medication Guide - Review Checklist | Inspection Checklist
Lecture 429PI Vs. Medication Guide Comparison
Lecture 430Patient Information Leaflet (PIL) vs Medication Guide
Lecture 431Label Components | Key considerations for effective designing of label
Lecture 432Label Review Checklist
Lecture 433Pharmaceutical Artwork Design Specification Worksheet - Complete Tracker
Lecture 434Color Proofing, Dielines & Version Control
Lecture 435CDR File - Monocarton | Outercarton | Keyline | Design Parameters
Lecture 436Injection Labels - Labels and Cartons
Lecture 437Various Design Component Placement Understanding (Injectables)
Lecture 438Concept of Logo File | Open and Curve File Importance
Lecture 439QC and Proof Reading in Labelling and Artwork
Lecture 440QC and Proofreading Checklist
Lecture 441Template Management and Creative Brief
Lecture 442Pre approval Labelling | ANDA Labelling | ANDA Labelling
Lecture 443Post approval Labelling | PAS | CBE-30 | Annual Reportable Changes
Lecture 444Decision Tree - PAS CBE-0 CBE-30 Annual Reportable Change Determination
Lecture 445Bulk Pack Labelling
Lecture 446Bulk Pack Labelling Checklist
Lecture 447OTC vs Prescription Labelling | Claim Limitations & Consumer Safety Requirements
Lecture 448OTC vs Prescription (Rx) Label Checklist
Lecture 449OTC Approval Matrix
Lecture 450OTC Claim Risk Scoring System
Section 25Evidence Based Decision Making | Combine evidences for decision making | Do we need more evidence?
Lecture 451Evidence Based Decision Making | Combine evidences for decision making | Do we need more evidence?
Lecture 452RWD and RWE | Potential sources of RWE | Traditional RCTs vs. RWE | Case Study - RWE Programs | Influencing HCP decision-making
Lecture 453RWD and RWE in Product Lifecycle Management
Lecture 454RWD and RWE - Fit to use | Assessment
Lecture 455RWD data sources | Different types | Detailed understanding of each class
Lecture 456RWD Study Design
Lecture 457RWE Published Tool | Insights on commonly used tools
Lecture 458Healthcare Reimbursement Models : Value Based Care | Fee for Service (FFS) Model | Other Reimbursement Models
Lecture 459Consensus Narrative Review
Lecture 460Electronic Patient Data | EMR | EHR | Differences | Software architecture and characteristics
Lecture 461Active Surveillance Schemes | Active Case Finding |Sentinel Surveillance | Cohort Studies | Vaccine Safety Surveillance | Pharmacovigilance Programs | Disease Registries |Event Monitoring
Lecture 462RWD Characteristics
Lecture 463RCT vs. RWE Comparison | Case Based Analysis
Lecture 464RCT and RWE Comparison
Section 26Working on Healthcare Datasets
Lecture 465Introduction to Healthcare Datasets
Lecture 466Dataset 1: Claims Data (Insurance)
Lecture 467Dataset 2: Retail Pharmacy Prescription Data
Lecture 468Dataset 3: Longitudinal Patient Data
Lecture 469Characteristics of Different Set of Healthcare Data
Lecture 470Reimbursement and Pricing Datasets
Lecture 471RWE Data Sources & Quality Considerations Checklist | Case Based Analysis
Lecture 472Triangulation and benchmarking | Enhancing Data Validation Through Cross-Referencing
Lecture 473RWD & RWE Case Database
Lecture 474RWE Large Dataset for Data Crunching Exercises |Data cleaning & preprocessing | Comparative Effectiveness Analysis
Section 27AI Tools, Ethics and Future Landscape
Lecture 475AI Reg Tools - Review | Understanding Capabilities
Lecture 476Regulatory Authority View on AI Adoption
Lecture 477Data Sensitivity | Levels | Consequences | Management
Lecture 478Governance Flowchart – AI Tools in GxP Environments
Section 28AI Tools
Lecture 479RA Example - Generalist Vs. Specialist AI Tools
Lecture 480AI Generalist Overview (Life Science Focus)
Lecture 481Horizontal vs Vertical AI Tools
Lecture 482AI Tool Assessment Test
Lecture 483Citation Verification Workflow | AI Tools Management | Hallucination and HITL Action Plan
Section 29Prompt Engineering
Lecture 484Prompt Engineering – Basic Foundations of Prompt Writing | Different Prompt Framework | Case Based Examples
Lecture 485Special Prompting Structure - Case Based Prompt Designing
Lecture 486Special Prompting Structure - Case Based Prompt Designing
Lecture 487Workflow for writing AI Prompts with Life Science Industry Use Cases
Lecture 488PE Parameters | Controlling Creativity, Accuracy, and Output Behavior for Life-Science Applications | Simulation based decision making
Lecture 489How to adjust the parameters | Techniques
Lecture 490Creating A Detailed Regulatory Prompt | Designing Structured Prompt in Code Editor